Smith+Nephew Q3 2025 Trading Report Date Set
Ticker: SNNUF · Form: 6-K · Filed: Oct 16, 2025 · CIK: 845982
| Field | Detail |
|---|---|
| Company | Smith & Nephew PLC (SNNUF) |
| Form Type | 6-K |
| Filed Date | Oct 16, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $5.8 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings-date, trading-report, medical-technology
TL;DR
SN dropping Q3 earnings Nov 7th, mark your calendars.
AI Summary
Smith+Nephew plc announced on October 16, 2025, that its third quarter 2025 trading report, covering the period ended September 27, 2025, will be released on Thursday, November 7, 2025. The company, a global medical technology firm, will also host an analyst presentation following the announcement.
Why It Matters
This announcement provides investors with a specific date to anticipate the company's financial performance update for the third quarter of 2025.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a future earnings report date and does not contain new financial information or material changes.
Key Players & Entities
- Smith+Nephew plc (company) — Registrant and subject of the report
- November 7, 2025 (date) — Date of the Q3 2025 trading report release
- September 27, 2025 (date) — End date of the third quarter 2025 trading period
- LSE: SN (company) — Stock ticker for Smith+Nephew on the London Stock Exchange
- NYSE: SNN (company) — Stock ticker for Smith+Nephew on the New York Stock Exchange
FAQ
When will Smith+Nephew announce its third quarter 2025 trading report?
Smith+Nephew will announce its trading report for the third quarter ended 27 September 2025 on Thursday, November 7, 2025.
What period does the upcoming trading report cover?
The trading report will cover the third quarter ended 27 September 2025.
What is the company's primary business?
Smith+Nephew is a global medical technology company.
Will there be a presentation for analysts following the report?
Yes, the company will host an analyst presentation following the announcement.
What are Smith+Nephew's stock exchange tickers?
Smith+Nephew is listed on the London Stock Exchange as LSE: SN and on the New York Stock Exchange as NYSE: SNN.
Filing Stats: 888 words · 4 min read · ~3 pages · Grade level 14.7 · Accepted 2025-10-16 08:50:26
Key Financial Figures
- $5.8 billion — countries and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent
Filing Documents
- a6464d.htm (6-K) — 24KB
- 0001654954-25-011851.txt ( ) — 25KB
Forward-looking Statements
Forward-looking Statements   This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at ww
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.             Smith & Nephew plc     (Registrant)             Date: October 16, 2025 By: /s/ Helen Barraclough     Helen Barraclough     Company Secretary